Atyr Pharma WKN: A2PM86 ISIN: US0021202025 Forum: Aktien User: Spottford

genau anzeigen den vividfantas den kerl

Klar

🥸🤣🥳🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🦎

du mußt dein schuko auto halt verstecken damt die kids nicht rankommen

https://sarcoidosisnews.com/news/efzofitimod-boosts-life-quality-pulmonary-sarcoidosis-adults-trial/

Treatment with Atyr Pharma’s efzofitimod, known as EFZO-FIT for short, led to improvements in general health-related quality of life and reductions in fatigue for adults with pulmonary sarcoidosis taking part in a Phase 3 clinical trial, according to new data. Consistent with previously announced top-line results, these new data did show that the trial, dubbed EFZO-FIT (NCT05415137), failed to meet its main goal of demonstrating that efzofitimod significantly reduced the need for standard corticosteroids in adults with pulmonary sarcoidosis. Still, other benefits — notably a potentially reduced reliance on steroids and better quality of life related to lung health — were observed. The developer believes these new data demonstrate that use of the investigational therapy can lead to meaningful daily life gains for pulmonary sarcoidosis patients. “Despite missing the primary [goal] of the study, efzofitimod has clearly demonstrated the potential to durably improve multiple disease-related health outcomes, including cough, shortness of breath, fatigue and general health,” Sanjay Shukla, MD, president and CEO of Atyr, said in a company press release announcing the data’s presentation in a late-breaking abstract at the European Respiratory Society (ERS) Congress 2025, held last week in Amsterdam. The results were shared at ERS by Daniel Culver, the trial’s principal investigator and chair of Cleveland Clinic’s department of pulmonary medicine, in an oral presentation titled “EFZO-FIT: The Largest Ever Interventional Trial in Pulmonary Sarcoidosis.” According to Shukla, “these consistent clinical benefits reinforce our belief in efzofitimod’s potential to meaningfully improve quality of life and reduce reliance on chronic steroids for pulmonary sarcoidosis patients.”

tamy: ja, schlanke 4.000 teile....nur zum speilen aber vielleicht werden es ja 20.000 euro....nice to have...neue bezüge für den lambo.....die alten haben die kids versaut

Sundsi knows best ❤️

SQUUUUUEEEEEEEEEEEEEEEEEEZZZZZZZEEEEEEEEEEE anytime 🚀🚀🚀